RARE Act

This bill, the RARE Act (S 3716), clarifies how orphan drug exclusivity is granted under U.S. law. It changes the definition from "same rare disease or condition" to "same approved use or indication" for determining when a drug can receive 7 years of market exclusivity after approval. This means exclusivity now applies specifically to the drug's approved medical use (e.g., treating a particular symptom or stage of a rare disease), not just the broader disease label. The change directly affects drug manufacturers developing orphan drugs and the FDA's approval process, ensuring exclusivity is tied to specific, approved uses rather than the general disease category. The amendments apply retroactively to all drugs already designated as orphan drugs.